Results of the STAMPEDE randomized clinical trial were published in the Lancet. Like the HORRAD trial (see below), they found there was no survival benefit to radiation debulking among all newly diagnosed men with metastases (Stage M1). Unlike the HORRAD trial, they utilized higher radiation doses.
Newly diagnosed men were treated with standard of care (which at the time meant ADT and docetaxel in 18% of the men) and were randomized to no radiation debulking or hypofractionated radiation, consisting of either:
- 55 Gy in 20 daily treatments, or
- 36 Gy in 6 weekly treatments (note: this bioequivalent dose is 15% higher)
- Survival increased by 32% (hazard ratio = 0.68) in 819 oligometastatic men
- 3 yr survival was 81% with debulking vs 73% without debulking
- No survival increase among the 1,120 polymetastatic men (defined as visceral metastases or 4 or more bone metastases with at least 1 outside the axial skeleton)
Adverse events from the radiation were generally mild:
- 5% had grade 3 (serious) or higher acute urinary or rectal side effects
- 4% had grade 3 (serious) or higher late-term urinary or rectal side effects
Based on this and their other randomized clinical trials, men with lower metastatic burden should be treated with ADT+Zytiga or ADT+docetaxel, followed in 2 months with local hypofractionated radiation. Men with higher metastatic burden should be treated with ADT+Zytiga or ADT+docetaxel (it is unknown whether ADT+Zytiga+docetaxel adds any additional benefit). Metastasis-directed therapy is under investigation.
(Update 2/18/2021) Because controversy exists in how to define "low metastatic burden," Ali et al. undertook a secondary analysis of the STAMPEDE trial. They found that the benefit of RT debulking was greatest in two groups:
- 1-3 bone metastases (M1b) with no visceral metastases
- Only non-pelvic lymph node metastases (M1a) with no visceral metastases
The survival benefit dropped off after 3 bone metastases. There was no benefit in anyone with any visceral metastases (M1c). Metastases are counted based on conventional imaging (bone scan/CT), so metastases found on PET scans do not count towards the total.
(Update 6/7/2022) Long-term follow-up (61 months) of the STAMPEDE trial, confirmed earlier findings:
- Survival increased by 36% if low burden
- Survival decreased by 11% if high burden (not statistically significant)
- No difference in quality of life
Boevé et al. reported the results of 432 men with bone metastases at 28 centers in the Netherlands from 2004 to 2014 (the HORRAD trial). They had received no previous treatments. They all had PSA > 20 ng/ml at the start of treatment and were under 80 years of age. They were randomized to receive either:
- Lifelong ADT (an LHRH agonist, starting with 4 weeks of an anti-androgen)
- Lifelong ADT + external beam radiation therapy (EBRT)
After 47 months median follow-up, the median overall survival was:
- 45 months in the group that received ADT + EBRT
- 43 months in the group that received ADT only
The authors also looked at survival differences based on:
- Number of bone metastases (<5, 5-15, >15)
- PSA at diagnosis (greater or less than 60 ng/ml)
- Gleason score
- Stage
- Age
- Performance status
- Painful bone metastases
None made any significant difference in survival.
The time to PSA progression was slightly longer among those who received EBRT (15 months vs. 12 months), but the statistical significance vanished after correction for patient characteristics.
These disappointing results conflict with several retrospective database analyses. This once again illustrates that only prospective randomized clinical trials can prove a causal relation, and that observational studies are confounded by the vagaries of patient selection; i.e., patients who receive debulking in actual clinical practice are the ones who would do better anyway. It is worth noting that a similar thing had occurred with breast cancer. Several retrospective studies had suggested that resection of the breast tumor plus axillary lymph nodes increased survival even when distant metastases were detected. However, Badwe et al. reported that when women were prospectively randomized to that treatment or no such treatment, there was no survival difference.
Because this trial began over a decade ago, it does not include radiation doses now considered to be curative (around 80 Gy). Nor does it include brachy boost therapy, which was shown to be superior to EBRT alone in high risk patients in the ASCENDE-RT randomized clinical trial. It is also unknown what effect whole-pelvic radiation or metastasis-directed therapy might have had, or whether prostatectomy with or without extended pelvic lymph node dissection (ePLND) may have increased survival.
(update 7/3/22) Dai et al. reported the results of an RCT among 200 men with oligometastatic PCa randomized to ADT alone or ADT with debulking the prostate with radiation or surgery (85% had surgery). After a median follow-up of 48 months:
- Radiographic progression was reduced by 57% by debulking
- Mortality was reduced by 56% by debulking
- PSA progression was reduced by 56% by debulking
These clinical trials began before CHAARTED, STAMPEDE, and LATITUDE clinical trials proved that early treatment with docetaxel and abiraterone improves survival in newly diagnosed metastatic men. It is unknown what effect debulking may have in men pre-treated with those systemic therapies.
Because radiation and prostatectomy have adverse effects, this study should make patients cautious about having any kind of debulking outside of a clinical trial.
